Barclays’s SOPHiA GENETICS SOPH Stock Holding History

Barclays’s Portfolio SOPH Stock Details SOPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-57,751	Closed	-$209K	–	5115
2022 Q2	$209K	Buy	+57,751	New	+$293K	﹤0.01%	3393

Other funds holding SOPH

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

AWA

Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Barclays's SOPH Position: Q3 2022 in Review

Barclays sold out of SOPHiA GENETICS (SOPH) in Q3 2022, closing a stake of 57,751 shares — an estimated $209K sold.

Barclays first reported a position in SOPH in Q2 2022 and held it in 1 quarter. The position peaked at $209K in Q2 2022. 34 funds tracked by Wall St. Rank hold SOPH as of Q3 2022.

Barclays reported no remaining SOPHiA GENETICS position as of Q3 2022 after selling out during the quarter.
Barclays sold 57,751 SOPHiA GENETICS shares in Q3 2022, an estimated $209K.
Barclays first reported a position in SOPHiA GENETICS in Q2 2022 and held it in 1 quarter.
Barclays's SOPHiA GENETICS position peaked at $209K in Q2 2022.
34 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.